Cargando…
Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relati...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867355/ https://www.ncbi.nlm.nih.gov/pubmed/34406915 http://dx.doi.org/10.1513/AnnalsATS.202006-722OC |
_version_ | 1784656038769721344 |
---|---|
author | Putcha, Nirupama Anzueto, Antonio R. Calverley, Peter M. A. Celli, Bartolomé R. Tashkin, Donald P. Metzdorf, Norbert Mueller, Achim Wise, Robert A. |
author_facet | Putcha, Nirupama Anzueto, Antonio R. Calverley, Peter M. A. Celli, Bartolomé R. Tashkin, Donald P. Metzdorf, Norbert Mueller, Achim Wise, Robert A. |
author_sort | Putcha, Nirupama |
collection | PubMed |
description | RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relationship between BMI and adverse outcomes in COPD. METHODS: This post hoc analysis included data from TIOSPIR (Tiotropium Safety and Performance in Respimat) (N = 17,116) and tiotropium-treated patients in UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) (N = 2,986). BMI classes (underweight [BMI < 20 kg/m(2)], normal weight [BMI 20 to <25 kg/m(2)], overweight [BMI 25 to <30 kg/m(2)], obesity class I [BMI 30 to <35 kg/m(2)], obesity class II [BMI 35 to <40 kg/m(2)], and obesity class III [BMI ⩾ 40 kg/m(2)]) were examined for adjusted associations with mortality, exacerbation, and nonfatal cardiovascular event risk using over 50,000 patient-years of cumulative follow-up data. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression models. RESULTS: In TIOSPIR, obesity prevalence was 22%, overweight 32%, and underweight 12%. The proportion of females was highest in obesity classes II and III. Overweight and obese participants had better baseline lung function versus other BMI classes; underweight participants were more likely to be current smokers. Underweight participants had a significantly higher risk of death (HR, 1.88; 95% CI, 1.62–2.20; P < 0.0001) and severe exacerbations (HR, 1.31; 95% CI, 1.16–1.47; P < 0.0001) versus normal-weight participants; however, overweight and obese participants were at lower to no additional risk. Results from UPLIFT were similar to TIOSPIR. CONCLUSIONS: These results suggest that there is a strong association between body weight, COPD events, and risk of death. A holistic management approach taking into account respiratory and cardiovascular risk factors and nutritional status is needed to improve the general well-being of patients with COPD. |
format | Online Article Text |
id | pubmed-8867355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Thoracic Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-88673552022-02-24 Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT Putcha, Nirupama Anzueto, Antonio R. Calverley, Peter M. A. Celli, Bartolomé R. Tashkin, Donald P. Metzdorf, Norbert Mueller, Achim Wise, Robert A. Ann Am Thorac Soc Original Research RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relationship between BMI and adverse outcomes in COPD. METHODS: This post hoc analysis included data from TIOSPIR (Tiotropium Safety and Performance in Respimat) (N = 17,116) and tiotropium-treated patients in UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) (N = 2,986). BMI classes (underweight [BMI < 20 kg/m(2)], normal weight [BMI 20 to <25 kg/m(2)], overweight [BMI 25 to <30 kg/m(2)], obesity class I [BMI 30 to <35 kg/m(2)], obesity class II [BMI 35 to <40 kg/m(2)], and obesity class III [BMI ⩾ 40 kg/m(2)]) were examined for adjusted associations with mortality, exacerbation, and nonfatal cardiovascular event risk using over 50,000 patient-years of cumulative follow-up data. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression models. RESULTS: In TIOSPIR, obesity prevalence was 22%, overweight 32%, and underweight 12%. The proportion of females was highest in obesity classes II and III. Overweight and obese participants had better baseline lung function versus other BMI classes; underweight participants were more likely to be current smokers. Underweight participants had a significantly higher risk of death (HR, 1.88; 95% CI, 1.62–2.20; P < 0.0001) and severe exacerbations (HR, 1.31; 95% CI, 1.16–1.47; P < 0.0001) versus normal-weight participants; however, overweight and obese participants were at lower to no additional risk. Results from UPLIFT were similar to TIOSPIR. CONCLUSIONS: These results suggest that there is a strong association between body weight, COPD events, and risk of death. A holistic management approach taking into account respiratory and cardiovascular risk factors and nutritional status is needed to improve the general well-being of patients with COPD. American Thoracic Society 2022-02-01 /pmc/articles/PMC8867355/ /pubmed/34406915 http://dx.doi.org/10.1513/AnnalsATS.202006-722OC Text en Copyright © 2022 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org). |
spellingShingle | Original Research Putcha, Nirupama Anzueto, Antonio R. Calverley, Peter M. A. Celli, Bartolomé R. Tashkin, Donald P. Metzdorf, Norbert Mueller, Achim Wise, Robert A. Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT |
title | Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT |
title_full | Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT |
title_fullStr | Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT |
title_full_unstemmed | Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT |
title_short | Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT |
title_sort | mortality and exacerbation risk by body mass index in patients with copd in tiospir and uplift |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867355/ https://www.ncbi.nlm.nih.gov/pubmed/34406915 http://dx.doi.org/10.1513/AnnalsATS.202006-722OC |
work_keys_str_mv | AT putchanirupama mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT anzuetoantonior mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT calverleypeterma mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT cellibartolomer mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT tashkindonaldp mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT metzdorfnorbert mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT muellerachim mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift AT wiseroberta mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift |